Generate Biomedicines GENB
$9.54 −$0.83 (-8.00%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $9.90 +3.77%
Open$10.06
Prev close$10.37
Day range$9.40 – $10.58
Volume967.9K
Market cap$1.23B
P/E (TTM)–
Dividend yield–
GENB Stock News
Headlines matching Generate Biomedicines or the GENB ticker, most recent first.
- Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)
- Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24
- H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25
- H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 Positive
- Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
- Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22
- Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
- Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)
- Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)
- H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25 Positive
- Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
- Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 Positive
- H.C. Wainwright Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $16
- Goldman Sachs Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26 Positive
- Guggenheim Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $30
No comments yet — be the first to weigh in on GENB.
Sign in to join the discussion.